Full-Time

Vice President

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

Compensation Overview

$309k - $383k/yr

+ Annual Bonus + Equity

New Haven, CT, USA

Hybrid

Minimum 3 days onsite per week in New Haven, CT.

Category
Legal & Compliance (2)
,
Requirements
  • Have a Juris Doctor from an American Bar Association-accredited law school; be a licensed attorney in at least one U.S. state and in good standing in all states where you are licensed; and have the ability to obtain Connecticut in-house counsel registration
  • A minimum of 10 years of relevant experience with a pharmaceutical/biopharma company providing life sciences advice, counsel and support to pharma/biopharma companies
  • Demonstrated expertise in relevant federal and state laws, regulations, rules and guidance as well as industry codes and principles impacting pharmaceutical manufacturers, including but not limited to drug labeling, advertising and promotion, scientific exchange, market access communications, government reimbursement and product liability
  • Demonstrated experience supporting regulatory and commercialization teams including providing legal counsel on Medical, Legal, Regulatory review committees, development and implementation of promotional activities, market access communications, drug labeling, scientific exchange; product launch experience strongly preferred; buy and bill experience a plus
  • Experience supporting regulatory affairs and drug safety in pharmaceutical development and ongoing obligations
  • Knowledge of enforcement landscape, including relevant industry litigation, settlements, and corporate integrity agreement obligations
  • Demonstrated senior leadership and personnel management skills and experience
  • Litigation experience a plus
  • Additional requirements such as exceptional judgment, ethics, accountability, communication skills, ability to travel, onsite requirements (New Haven, CT) and other behavioral competencies as described in the posting
Responsibilities
  • Providing strategic, operational and tactical legal counsel and business advice related to the development and commercialization of Invivyd’s product(s) and product candidate(s)
  • Advising clients on FDA (and global regulatory authority) regulatory matters and compliance with laws, rules, regulations, guidance and industry standards that arise throughout a product lifecycle, including in the areas of product development, regulatory submissions, advertising and promotion, and drug safety
  • Providing legal counsel on health care laws, including the Federal Anti-Kickback Statute, FDCA, False Claims Act, PhRMA Code, FTC, HIPAA, CAN-SPAM, state laws on physician gifts/meals, Sunshine Act, state price transparency reporting, product liability statues and related health care legal obligations
  • Providing legal advice, business counsel, and material review and creation (e.g., informed consent forms, clinicaltrial.gov postings, FDA correspondence and submissions) to Clinical, Clinical Operations, Regulatory Affairs, Pharmacovigilance relating to clinical trial programs and drug development
  • Providing legal advice, business counsel and training (building and delivering) to the Marketing team on innovative marketing strategies, activities, programs and trainings, including serving as the Legal representative on the Company committee responsible for the review of advertising and promotional strategies and materials, digital and social media initiatives, and working with clients to develop appropriate and compliant strategies for interacting with healthcare providers and other stakeholders
  • Providing legal advice, business counsel and training (building and delivering) to the Market Access team, including advice on developing and implementing payer strategies, pre-approval information exchange materials, distribution models and materials, patient support programs, HEOR studies and communications
  • Providing legal advice, business counsel and training (building and delivering) to the Medical Affairs team on proactive and reactive communications (i.e., scientific exchange, research planning and support, publications), presentations, engagements and other activities; serving as Legal representative on the Company committee responsible for the review of select scientific exchange
  • Reviewing materials for Corporate Affairs (communications) team, including social media posts
  • Working closely with other Legal and Compliance department colleagues to provide consistent and efficient legal and compliance support to the Company. Supporting the creation, review, updating and training of corporate and healthcare compliance policies, SOPs, rules of engagement, and laws, regulations, guidance and codes
  • Providing and coordinating legal support as a member of cross-functional teams
  • Representing the Legal department on cross-functional initiatives and collaborating with other members of the Legal department on internal initiatives
  • Researching issues and supporting the company in providing a wide range of legal advice to internal clients
  • Managing outside counsel resourcing and budget for complex or nuanced areas of law, regulation or policy
  • Lead or support internal investigations on behalf of Legal; lead or support external investigations or litigation, independently, collaboratively, and/or with outside counsel support, as applicable
  • Potential for management of one or more legal teams (e.g., Contracts) and/or direct reports, in role currently or to be hired

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • DECLARATION Phase 3 trial fully enrolled with mid-2026 data readout for VYD2311 launch.
  • PEMGARDA revenue grew 31% sequentially in Q4 2025, validating antibody prophylaxis market demand.
  • Pipeline expansion into measles, RSV, and long COVID addresses multiple high-need viral indications.

What critics are saying

  • Low COVID community attack rates force 30% trial expansion, risking 6-9 month data delay.
  • Stock price below $1 triggers Nasdaq delisting risk, halting institutional investment and capital access.
  • Competing extended half-life COVID antibodies from AstraZeneca and Regeneron capture immunocompromised market share.

What makes Invivyd unique

  • Proprietary platform combines viral surveillance, predictive modeling, and antibody engineering for evolved immunity.
  • Targets immunocompromised populations underserved by traditional vaccines with monoclonal antibody prophylaxis.
  • FDA Fast Track designation for VYD2311 accelerates COVID-19 prevention development versus competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-5%

2 year growth

-1%
Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

TipRanks
Nov 17th, 2025
Invivyd Announces Common Stock Offering

Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.

Stock Titan
Aug 22nd, 2025
Invivyd Closes $57.5M Public Offering

Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.